Results 191 to 200 of about 14,735 (228)

Metabolism of the Isoflavone Derivative Structural Isomers ACF-02 and ACF-03 in Human Liver Microsomes. [PDF]

Pharmaceutics
Liang Z, Kim EH, Kim GY, Choi JH, Seo HJ, Liu KH, Cho M.   +6 more
europepmc   +1 more source

<i>CYP2D6</i> polymorphism rs1065852 significantly increases the risk of type 2 diabetes. [PDF]

Ann Med
Wei H, Zhao Q.
europepmc   +1 more source

A Phenotyping Tool for Seven Cytochrome P450 Enzymes and Two Transporters: Application to Examine the Effects of Clopidogrel and Gemfibrozil. [PDF]

Clin Pharmacol Ther
Aurinsalo L, Lapatto-Reiniluoto O, Kurkela M, Neuvonen M, Kiiski JI, Niemi M, Tornio A, Backman JT.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

CYP2C8 polymorphism among the Portuguese

Clinical Chemistry and Laboratory Medicine, 2006
AbstractCytochrome P450 2C8 (CYP2C8) is a polymorphic phase I drug-metabolising enzyme involved in the metabolism of a wide variety of xenobiotics, as well as a proposed player in the regulation of vascular tone. Polymorphisms in this gene may have an impact on the metabolism of therapeutic drugs such as paclitaxel and verapamil. In this report we have
Isa Cavaco, Vera L Ribeiro
exaly   +3 more sources

Interplay of UDP-Glucuronosyltransferase and CYP2C8 for CYP2C8 Mediated Drug Oxidation and Its Impact on Drug–Drug Interaction Produced by Standardized CYP2C8 Inhibitors, Clopidogrel and Gemfibrozil

Clinical Pharmacokinetics, 2023
Early investigations into drug-drug interactions (DDIs) involving cytochrome P450 2C8 (CYP2C8) have highlighted the complexity of interactions between CYP2C8 substrate drugs, including montelukast, desloratadine, pioglitazone, repaglinide, and cerivastatin (the latter two being OATP1B1 substrates), and standardized CYP2C8 inhibitors such as clopidogrel
Katsumi Iga, Akiko Kiriyama
openaire   +2 more sources

Evaluation of CYP2C8 Inhibition In Vitro: Utility of Montelukast as a Selective CYP2C8 Probe Substrate

Drug Metabolism and Disposition, 2011
Understanding the potential for cytochrome P450 (P450)-mediated drug-drug interactions is a critical step in the drug discovery process. Although in vitro studies with CYP3A4, CYP2C9, and CYP2C19 have suggested the presence of multiple binding regions within the P450 active site based on probe substrate-dependent inhibition profiles, similar studies ...
Brooke M, VandenBrink, Robert S, Foti, Dan A, Rock, Larry C, Wienkers, Jan L, Wahlstrom   +4 more
openaire   +2 more sources

GENETIC POLYMORPHISMS OF CYP2C8 IN JAPANESE POPULATION

Drug Metabolism and Disposition, 2003
CYP2C8 plays important roles in metabolizing therapeutic drugs and endogenous compounds. Although genetic polymorphisms of CYP2C8 were reported, there is little information on CYP2C8 polymorphisms in the Japanese population. In the present study, we screened for previously described polymorphisms in the coding region of this gene using polymerase chain
Miki, Nakajima, Yuto, Fujiki, Kumiko, Noda, Hiroki, Ohtsuka, Hisashi, Ohkuni, Satoru, Kyo, Masaki, Inoue, Yukio, Kuroiwa, Tsuyoshi, Yokoi   +8 more
openaire   +2 more sources

In Silico Prediction of CYP2C8 Inhibition with Machine-Learning Methods

Chemical Research in Toxicology, 2021
Cytochrome P450 2C8 (CYP2C8) is a major drug-metabolizing enzyme in humans and is responsible for the metabolism of ∼5% drugs in clinical use. Thus, inhibition of CYP2C8, which causes potential adverse drug events, cannot be neglected. The in vitro drug interaction studies guidelines for industry issued by the FDA also point out that it needs to be ...
Xiaoxiao Zhang, Piaopiao Zhao, Zhiyuan Wang, Xuan Xu, Guixia Liu, Yun Tang, Weihua Li   +6 more
openaire   +2 more sources

Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms

Biochemical and Biophysical Research Communications, 2002
Cytochrome P450 (CYP) 2C8 and 2C9 are polymorphic enzymes. The CYP2C8*3 and CYP2C9*2 are the major variant alleles in Caucasian populations. The enzymes encoded by these variant alleles have impaired function for the metabolism of several drug substrates.
Umit, Yasar, Stefan, Lundgren, Erik, Eliasson, Anna, Bennet, Björn, Wiman, Ulf, de Faire, Anders, Rane   +6 more
openaire   +2 more sources